Rationale for Using Cryocompression to Prevent Chemo-Induced Neuropathy

Video

Cryocompression demonstrates potential for preventing chemotherapy-induced neuropathy for those with gynecologic cancers, according to an expert from Duke University Medical Center.

Mary Katherine Montes de Oca, MD, spoke with CancerNetwork® in an interview at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer about the mechanism of action for cryocompression as an intervention for preventing peripheral neuropathy associated with chemotherapy for patients with gynecologic cancers.

Montes de Oca, an Obstetrics and Gynecology resident at Duke University Medical Center, indicated that cryocompression is a treatment that combines 2 strategies: compression therapy and cryotherapy on the patients’ hands and feet. By inducing vasoconstriction through this process, Montes de Oca states that cryocompression may reduce the likelihood of cytotoxic agents reaching the hands and feet that may cause neuropathy.

Data from a self-controlled trial indicated that patients who underwent cryocompression less frequently experienced moderate to severe symptoms of neuropathy compared with those who did not receive the intervention. At baseline, neuropathy symptoms were identified in 2.2% of cases where cryocompression was not used compared with 3.3% where it was used. At final assessment, the rate of neuropathy symptoms was 13.2% and 7.7% in each respective group.

Transcript:

Cryocompression is a combination of cold therapy and compression therapy on the hands and feet. The proposed mechanism is that the cold therapy and the compression therapy cause vasoconstriction, which then leads to decreased blood circulation to the hands and the feet, and then decreased delivery of chemotherapy or neurotoxic agents that cause neuropathy to the hands and feet.

There are a few options for the prevention of neuropathy. There are some medications that can be used for treatment once a patient is diagnosed with neuropathy. But for prevention, the only other intervention that has really shown promise is cryotherapy—just the cold therapy without the compression therapy. The goal of this study was to look at the two combined.

Reference

Montes de Oca MK, Unnithan S, Erkanli AE, et al. Use of cryocompression to reduce peripheral neuropathy in gynecologic cancer: a randomized controlled trial. Presented at: 2023 SGO Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, Florida.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
Related Content